# Prospect Venture Partners

> Prospect Venture Partners is a VC fund backing Biotechnology and Health Care. See 90 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Palo Alto, United States
- Total investments: 90
- Last investment: Sep 2016
- Lead investor: 21%
- Fund size: $180M
- Last fund: Aug 2010
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/prospect-venture-partners-lp/about/
- Website: http://www.prospectventurepartners.com

Prospect Venture Partners is a venture capital firm with over $1B of capital under management. The firm is dedicated to investing in outstanding biopharmaceutical and medical device companies. Prospect targets commercially attractive biomedical enterprises with outstanding entrepreneurial management teams, proprietary products, and innovativetechnologies with the potential for significant investment returns. The firm invests in companies with a wide variety of development and financing requirements including new company incubations, first and second venture financing rounds, and later stage private and public companies with proven business models requiring expansion capital.

## Contacts

5 contacts available for Prospect Venture Partners. Shizune tracks 3 team members at Prospect Venture Partners. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/prospect-venture-partners?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 36 | 40% |
| Health Care | 30 | 33% |
| Pharmaceutical | 18 | 20% |
| Medical | 16 | 18% |
| Medical Device | 14 | 16% |

26 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 29 | 32% |
| Series A | 15 | 17% |
| Series C | 15 | 17% |
| Series D | 12 | 13% |
| Funding Round | 8 | 9% |

9 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 47 | 52% |
| Belgium | 1 | 1% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| David Schnell | Managing Director | 16 | https://shizune.co/investors/profile/david-schnell |
| Russell Hirsch | Managing Director | 5 | https://shizune.co/investors/profile/russell-hirsch |
| Russell Hirsch | Managing Director | 11 | https://shizune.co/investors/profile/russell-hirsch-8da2 |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| SentreHEART | SentreHEART, Inc., based in Redwood City, California, is a privately held medical device company that manufacturers the LARIAT Suture Delivery Device for remote delivery of a pre-tied suture loop. Innovation in catheter and suture delivery technology enables physicians to remotely deliver a 40mm pre-tied suture loop for immediate and complete softtissue closure through access as small as 4.3mm and with no metal, clips or fabrics left behind. Regulatory clearance for soft tissue ligation and approximation has been received in the US, Europe, and Canada. | $35M | Series D | Sep 27, 2016 |  |
| NGM Biopharmaceuticals | NGM Biopharmaceuticals is a privately-held drug discovery company committed to identifying transformational medicines that dramatically improve human health. Based on emerging human clinical and genetic observations, the company has devised several innovative experimental approaches to discover new therapies for the treatment of metabolic andcardiovascular diseases. The company's current focus is on the gastrointestinal endocrine system, with an aim to identify novel factors implicated in the pathogenesis of type 2 diabetes and the apparent resolution of this grievous disease in patients who have undergone gastric bypass surgery. | $57.5M | Series D | Mar 23, 2015 |  |
| Nora Therapeutics | Nora Therapeutics is a specialty biopharmaceutical company focused on developing therapeutics to address clinical unmet needs in reproductive medicine.Nora’s lead compound, NT100, is a novel treatment being studied to improve pregnancy success rates and outcomes for women who have undergone multiple unsuccessful in vitro fertilization (IVF)procedures. NT100 is a novel biologic agent similar to a naturally occurring protein in the female reproductive tract. NT100’s mechanism of action may better enable embryo implantation and pregnancy maintenance by optimizing maternal-fetal immune tolerance. | $18M | Series B | Apr 17, 2014 |  |
| Element Science | Element Science is a medical device and digital health company that develops solutions at the intersection of clinical-grade wearable devices, machine learning algorithms, and lifesaving therapies to address the needs of high-risk cardiovascular patients, primarily as they transition from the hospital to home. The company developing a proprietarynext-generation wearable digital platform that unites patient-centric human factor engineering, sophisticated machine learning algorithm development principles, and rigorous electromechanical medical device development standards.The company was founded in 2011 and is headquartered in San Francisco, California. | $12.5M | Series A | Mar 19, 2014 |  |
| NinePoint Medical | NinePoint Medical, Inc. is a transformational medical device company developing innovative, real-time, in vivo pathology devices. The company's first goal is to develop a device that enables remote pathology, or telepathology, which would facilitate immediate review of images during diagnostic procedures. This capability could potentiallyprovide physicians with immediately actionable information and eventually allow them to pursue therapeutic remedies at the time of diagnosis. This convergence of access, diagnosis and treatment during one procedure is expected to improve patient experiences and outcomes, improve the efficiency of care and provide important savings to the healthcare system. Headquartered in Cambridge, Mass., NinePoint is backed by Third Rock Ventures and Prospect Venture Partners. | $34M | Series B | Mar 18, 2014 |  |
| NGM Biopharmaceuticals | NGM Biopharmaceuticals is a privately-held drug discovery company committed to identifying transformational medicines that dramatically improve human health. Based on emerging human clinical and genetic observations, the company has devised several innovative experimental approaches to discover new therapies for the treatment of metabolic andcardiovascular diseases. The company's current focus is on the gastrointestinal endocrine system, with an aim to identify novel factors implicated in the pathogenesis of type 2 diabetes and the apparent resolution of this grievous disease in patients who have undergone gastric bypass surgery. | $50M | Series C | Jul 18, 2013 |  |
| SentreHEART | SentreHEART, Inc., based in Redwood City, California, is a privately held medical device company that manufacturers the LARIAT Suture Delivery Device for remote delivery of a pre-tied suture loop. Innovation in catheter and suture delivery technology enables physicians to remotely deliver a 40mm pre-tied suture loop for immediate and complete softtissue closure through access as small as 4.3mm and with no metal, clips or fabrics left behind. Regulatory clearance for soft tissue ligation and approximation has been received in the US, Europe, and Canada. | $26M | Series C | Jun 04, 2012 |  |
| Satori Pharmaceuticals | Satori Pharmaceuticals is a neuroscience company focused on the discovery and development of disease-modifying therapies for Alzheimer's disease, Parkinson's disease and other neurodegenerative disorders. | $15M |  | Feb 23, 2012 |  |
| DFine | DFine is a highly innovative medical device company focusing on providing physicians new and promising therapy for managing compression fractures of the spine while providing patients with much-needed pain relief. In July 2016, the company was acquired by Merit Medical Systems. |  |  | Nov 08, 2011 |  |
| Topica Pharmaceuticals | TOPICA Pharmaceuticals, Inc. is a privately held clinical research stage pharmaceutical company focused on developing luliconazole for the treatment of onychomycosis, fungal infections of the nail. More than 35 million Americans are estimated to suffer from onychomycosis for which treatmentoptions are limited. In addition to luliconazole’shighly potent anti-fungal activity and excellent safety profile, the molecule is able to rapidly cross the nail plate reaching the site of the infection in the nail bed. In a Phase 1/2a clinical trial completed in 2011, TOPICA demonstrated the ability of its3 proprietary 10 percent luliconazole solution to rapidly cross the nail plate and was well tolerated by patients. The company is now focused on conducting a robust dose finding and proof of efficacy study with luliconazole in onychomycosis starting in mid 2012 with the goal of making luliconazole the first highly effective and safe topical therapy for the treatment of onychomycosis. | $27M | Series B | Oct 18, 2011 |  |

10 of 90 investments shown.

## Co-investors
- [Venrock](https://shizune.co/investors/profile/venrock) — VC Fund, 14 deals together
- [MPM Capital](https://shizune.co/investors/profile/mpm-capital) — VC Fund, 10 deals together
- [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund, 9 deals together
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund, 7 deals together
- [Sutter Hill Ventures](https://shizune.co/investors/profile/sutter-hill-ventures) — VC Fund, 7 deals together
- [Versant Ventures](https://shizune.co/investors/profile/versant-ventures) — VC Fund, 7 deals together

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Prospect Venture Partners invest in?

Prospect Venture Partners invests primarily in Biotechnology, Health Care and Pharmaceutical startups, most often at Series B and Series A stage. Most of the 90 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Prospect Venture Partners?

Public channels for Prospect Venture Partners include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Prospect Venture Partners?

The team at Prospect Venture Partners includes David Schnell (Managing Director), Russell Hirsch (Managing Director) and Russell Hirsch (Managing Director). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co